Dynavax Technologies (NASDAQ:DVAX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX) in a report published on Friday morning,Benzinga reports. They currently have a $29.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ Q4 2024 earnings at $0.04 EPS, FY2024 earnings at $0.18 EPS and FY2025 earnings at $0.26 EPS.

Separately, The Goldman Sachs Group cut their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th.

Dynavax Technologies Trading Up 8.2 %

Dynavax Technologies stock traded up $0.99 during trading on Friday, hitting $13.01. The company’s stock had a trading volume of 5,099,684 shares, compared to its average volume of 2,418,806. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 118.28 and a beta of 1.34. The stock’s fifty day moving average is $11.16 and its 200 day moving average is $11.24. Dynavax Technologies has a 1-year low of $9.74 and a 1-year high of $15.01. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. The firm had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. During the same period in the prior year, the firm posted $0.03 earnings per share. As a group, equities research analysts predict that Dynavax Technologies will post 0.16 EPS for the current year.

Institutional Investors Weigh In On Dynavax Technologies

Several hedge funds have recently modified their holdings of DVAX. Texas Permanent School Fund Corp grew its position in shares of Dynavax Technologies by 1.3% in the 1st quarter. Texas Permanent School Fund Corp now owns 113,128 shares of the biopharmaceutical company’s stock worth $1,404,000 after acquiring an additional 1,467 shares in the last quarter. Duality Advisers LP bought a new stake in shares of Dynavax Technologies in the 1st quarter worth $227,000. ClariVest Asset Management LLC raised its stake in shares of Dynavax Technologies by 11.5% in the 1st quarter. ClariVest Asset Management LLC now owns 108,752 shares of the biopharmaceutical company’s stock worth $1,350,000 after buying an additional 11,235 shares in the last quarter. ProShare Advisors LLC raised its stake in shares of Dynavax Technologies by 8.3% in the 1st quarter. ProShare Advisors LLC now owns 35,269 shares of the biopharmaceutical company’s stock worth $438,000 after buying an additional 2,691 shares in the last quarter. Finally, Mizuho Markets Americas LLC grew its holdings in shares of Dynavax Technologies by 16.9% in the 1st quarter. Mizuho Markets Americas LLC now owns 852,057 shares of the biopharmaceutical company’s stock worth $10,574,000 after acquiring an additional 123,300 shares during the last quarter. 96.96% of the stock is currently owned by hedge funds and other institutional investors.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.